The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
She joins Enveda from Gilead Sciences
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
This new fund is amongst the largest for the sector in India
Subscribe To Our Newsletter & Stay Updated
